

Snehal M Gaikwad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4007595/publications.pdf>

Version: 2024-02-01

16
papers

418
citations

840776

11
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

757
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing Clinically Relevant Acquired Chemoresistance Models in Epithelial Ovarian Cancer Cell Lines. <i>Bio-protocol</i> , 2022, 12, e4310.	0.4	1
2	A Small Molecule Stabilizer of the MYC G4-Quadruplex Induces Endoplasmic Reticulum Stress, Senescence and Pyroptosis in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2952.	3.7	24
3	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2221-2232.	4.1	7
4	Mouse tumor susceptibility genes identify drug combinations for multiple myeloma. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 2020, .	0.8	2
5	Characterization of clinically used oral antiseptics as quadruplex-binding ligands. <i>Nucleic Acids Research</i> , 2018, 46, 2722-2732.	14.5	27
6	Soft drug-resistant ovarian cancer cells migrate via two distinct mechanisms utilizing myosin II-based contractility. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 392-405.	4.1	22
7	Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. <i>Nature Communications</i> , 2018, 9, 4229.	12.8	131
8	Abstract 5850: Nrf2-mediated oxidative stress response is altered during acquired resistance to the proteasome inhibitor, oprozomib, in multiple myeloma. , 2018, , .		0
9	Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2008-2021.	4.1	29
10	Abstract 194: Effective targeting of MYC expression with a novel nucleic acid binding (G4-quadruplex) small molecule coupled with HDAC inhibition synergizes to limit myeloma growth. , 2017, , .		0
11	A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis. <i>Biochemical Pharmacology</i> , 2016, 122, 10-22.	4.4	18
12	Differential activation of NF- κ B signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 61, 90-102.	2.8	31
13	Magnetic nanoparticle-mediated hyperthermia therapy induces tumour growth inhibition by apoptosis and Hsp90/AKT modulation. <i>International Journal of Hyperthermia</i> , 2015, 31, 909-919.	2.5	34
14	IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. <i>Cancer Letters</i> , 2014, 354, 254-262.	7.2	55
15	Non-Invasive Imaging of Phosphoinositide-3-Kinase-Catalytic-Subunit-Alpha (PIK3CA) Promoter Modulation in Small Animal Models. <i>PLoS ONE</i> , 2013, 8, e55971.	2.5	21
16	Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 418-31.	1.0	16